14 completed, 7 recruiting, 6 unknown, 4 terminated. 15 Phase 2, 14 Phase 1, 9 Phase 3, 1 Not applicable.
Follow Zai Lab (Shanghai) Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia Xanomeline and trospium chloride (KarXT) - Schizophrenia Disorder | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 250 | 2026-09-20 | 2026-09-03 | |
| A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers ZL-1503 - Healthy Volunteers | Phase 1 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 36 | 2026-09-03 | 2026-08-20 |
| Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors ZL-6201 - Solid Tumors, Sarcomas | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 180 | 2026-03-02 | 2026-07-23 |
| A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease ZL-1109 (VRDN-003), Placebo - Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | Zai Lab (Shanghai) Co., Ltd. | 108 | 2025-12-05 | 2026-09-09 |
| A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis ZL-1503, Placebo - Atopic Dermatitis (AD) | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 84 | 2025-12-01 | 2026-08-07 |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) ZL-1310, Investigator's Choice of Therapy - Small-cell Lung Cancer | Phase 3 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 480 | 2025-11-30 | 2026-10-16 |
| A Study of ZL-1310 in Participants With Selected Solid Tumors ZL-1310 - Solid Tumors | Phase 1 / Phase 2 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 166 | 2025-05-12 | 2026-08-21 |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer ZL-1310, Atezolizumab, Carboplatin - SCLC | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 339 | 2024-01-23 | 2026-10-16 |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Repotrectinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 190 | 2023-12-21 | 2026-09-22 |
| To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies Tisotumab Vedotin - Solid Malignancies | Phase 1 | Completed | Zai Lab (Shanghai) Co., Ltd. | 19 | 2023-06-16 | 2023-11-27 |
| A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia Xanomeline and Trospium Chloride Capsules, Placebo - Schizophrenia | Phase 3 | Completed | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 202 | 2023-05-29 | 2025-12-17 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) efgartigimod IV, Placebo - Lupus Nephritis | Phase 2 | Completed | argenx | 73 | 2023-02-21 | 2025-12-18 |
| A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi Niraparib - Epithelial Ovarian Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 35 | 2022-06-01 | 2022-05-23 |
| The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors MRTX849 - Advanced or Metastatic Solid Tumor | Phase 1 | Unknown | Zai Lab (Shanghai) Co., Ltd. | 22 | 2022-05-30 | 2023-02-27 |
| Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. Niraparib, Anlotinib - Platinum-resistant Recurrent Clear Cell Ovarian Cancer | Phase 2 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 6 | 2021-12-15 | 2023-01-31 |
| Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma Niraparib - Endometrial Carcinoma, Serous Carcinoma | Phase 2 | Recruiting | Shandong University | 83 | 2021-06-01 | 2024-01-05 |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumor(GIST) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 108 | 2020-11-25 | 2026-04-03 |
| A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma MGD013 - Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma | Phase 1 | Terminated | Zai Lab (Shanghai) Co., Ltd. | 92 | 2020-10-29 | 2024-01-29 |
| A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC Margetuximab Margetuximab-IV - HER2 Positive Metastatic Breast Cancer | Phase 1 | Completed | Zai Lab (Shanghai) Co., Ltd. | 16 | 2020-08-25 | 2021-06-14 |
Showing 20 of 36. Sign in to see all of them.
Ovarian Neoplasms (4) · Stomach Neoplasms (4) · Small Cell Lung Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Gastrointestinal Stromal Tumors (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Schizophrenia (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Hepatocellular (1)
niraparib (6) · Trastuzumab (3) · Capecitabine (2) · Carboplatin (2) · Etoposide (2) · anlotinib (2) · atezolizumab (2) · brivanib (2) · margetuximab (2) · repotrectinib (2) · ripretinib (2) · trospium chloride (2) · xanomeline (2) · BID protein, human (1) · Crizotinib (1)
China (30) · United States (9) · Germany (5) · Italy (5) · Poland (5) · Spain (5) · France (4) · Japan (4) · South Korea (4) · Taiwan (4) · United Kingdom (4) · Australia (3) · Belgium (3) · Hungary (3) · Netherlands (3)
Zai Lab (2) · Bingzhong Zhang, Dr (1) · Cuizhi Geng (1) · Dongqing Lv, Dr (1) · Ge Lou (1) · Guiling Li, Dr (1) · Hong Zheng (1) · Hongmin Pan (1) · Jianhua Shi, Dr (1) · Lingying Wu (1) · Meili Sun, Dr (1) · Min Yan (1)
PMID 30093503, PMID 31439812, PMID 32269053, PMID 32965540, PMID 33263418, PMID 33453391, PMID 36244398, PMID 37440217, PMID 38197815, PMID 38308771, PMID 38745967, PMID 38751523, PMID 39074931, PMID 40341199, PMID 40445839, PMID 41639379, PMID 41811823
2017 (1)